Ginkgo Bioworks Holdings, Inc. (DNA): Price and Financial Metrics
GET POWR RATINGS... FREE!
DNA Stock Price Chart Interactive Chart >
DNA Price/Volume Stats
|Current price||$3.21||52-week high||$15.86|
|Prev. close||$2.96||52-week low||$2.09|
|Day high||$3.22||Avg. volume||18,197,439|
|50-day MA||$3.26||Dividend yield||N/A|
|200-day MA||$7.75||Market Cap||5.65B|
Ginkgo Bioworks Holdings, Inc. (DNA) Company Bio
Ginkgo Bioworks Holdings, Inc. develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is based in Boston, Massachusetts.
Most Popular Stories View All
DNA Latest News Stream
|Loading, please wait...|
DNA Latest Social Stream
View Full DNA Social Stream
Latest DNA News From Around the Web
Below are the latest news stories about Ginkgo Bioworks Holdings Inc that investors may wish to consider to help them evaluate DNA as an investment opportunity.
Thursday’s Top Analysts Upgrades and Downgrades: Caesars Entertainment, Chevron, Exact Sciences, Exxon Mobil, Gap, Ginkgo Bioworks, Home Depot, New York Mortgage Trust, Novavax, NOV, SoFi Technologies and More
Thursday''s top analyst upgrades and downgrades included Caesars Entertainment, Chevron, Exact Sciences, Exxon Mobil, Gap, Ginkgo Bioworks, Home Depot, New York Mortgage Trust, Novavax, NOV and SoFi Technologies.
Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that management is scheduled to participate in the following upcoming conferences:
Ginkgo Bioworks (DNA) hit a post-IPO low of $4.24 today. The company began trading in September through a SPAC merger.
Completed Audit Committee evaluation and restated Q2 2021 unaudited interim financial statements Announces strategic realignment to support future growth strategies Consolidated net revenue increased 80% in the third quarter of 2021 compared to the third quarter of 2020 Launched Cronos Group's first cultured cannabinoid gummy and vape products under Spinach FEELZ™ brand Spinach® held a double-digit market share in the gummies category in Canada in the third quarter of 2021 TORONTO, Feb. 18, 2022
With sentiment souring over inflation and other concerns, contrarians may have an opportunity to bank on certain stocks to buy like these.
DNA Price Returns